Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$1.01 CAD
Change Today +0.02 / 2.02%
Volume 14.0K
As of 3:59 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

imris inc (IM) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/22/14 - C$1.69
52 Week Low
12/16/14 - C$0.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMRIS INC (IM)

Related News

No related news articles were found.

imris inc (IM) Related Businessweek News

No Related Businessweek News Found

imris inc (IM) Details

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.

121 Employees
Last Reported Date: 03/31/15
Founded in 2005

imris inc (IM) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $450.0K
Principal Accounting Officer and Director of ...
Total Annual Compensation: $160.0K
Executive Vice President of Operations
Total Annual Compensation: $250.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $285.0K
Executive Vice President of Global Customer S...
Total Annual Compensation: $255.0K
Compensation as of Fiscal Year 2014.

imris inc (IM) Key Developments

IMRIS, Inc.'s VISIUS® iCT Receives Health Canada License Allowing for Sales and Marketing in the Country

IMRIS Inc. announced that VISIUS® iCT, ceiling-mounted intraoperative computed tomography scanner, has received Health Canada licensing allowing for sales and marketing in the country. VISIUS iCT provides dose management together with diagnostic quality imaging during the surgical procedure to assist surgeons in critical decision making. Developed for the neurosurgery and spine surgery markets, VISIUS iCT has the 64-slice Siemens SOMATOM® Definition AS scanner as its core technology – making it the quality computed tomography imagery in an operating room. Unlike other mobile intraoperative CT systems on the market, the VISIUS iCT can support complex brain tumor resection and neurovascular procedures. The scanner effortlessly moves into and out of the operating room during surgery using ceiling-mounted rails to ease workflow. This enables multiple room configurations to meet both clinical requirements and increase utilization without compromising image quality or exam speed. Patient transport and the need for floor-mounted rails used in other systems is eliminated which opens up valuable OR space and allows unimpeded movement of surgical equipment and simplified infection control. In addition, VISIUS iCT features a suite of software applications such as 3D volume rendering to aid in surgical planning and dose reduction which considers each patient's characteristics to maximize image quality and minimize dose. The system software allows healthcare practitioners to visualize dosage prior to scan and adjust settings based on the specific clinical need with detailed dosage reports produced after each scan.

IMRIS, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the First Quarter of 2015 and Earnings Guidance for the Full Year of 2015

IMRIS, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of USD 9,558,000 against USD 9,985,000 a year ago. Operating loss was USD 4,270,000 against USD 19,834,000 a year ago. Net loss before taxes was USD 6,472,000 against USD 21,503,000 a year ago. Net loss was USD 6,846,000 or USD 0.13 per basic and diluted share against USD 21,615,000 or USD 0.42 per basic and diluted share a year ago. Adjusted LBITDA was USD 3,286,000 against USD 18,767,000 a year ago. For the full year, the company reported total revenue of USD 28,891,000 against USD 46,042,000 a year ago. Operating loss was USD 22,919,000 against USD 39,305,000 a year ago. Net loss before taxes was USD 29,924,000 against USD 41,856,000 a year ago. Net loss was USD 6,472,000 or USD 0.58 per basic and diluted share against USD 21,503,000 or USD 0.83 per basic and diluted share a year ago. Net loss was USD 30,166,000 against USD 42,000,000 a year ago. Net cash used in operating activities was USD 10,910,000 against USD 40,581,000 a year ago. Acquisition of property, plant and equipment was USD 2,510,000 against USD 9,179,000 a year ago. Acquisition of intangible assets was USD 140,000 against USD 227,000 a year ago. Adjusted EBITDA was USD 6,472,000 against USD 21,503,000 a year ago. Adjusted LBITDA was USD 18,559,000 against USD 33,934,000 a year ago. The company anticipates its 2015 first quarter revenues will be in the range of USD 3.5 million to USD 4.5 million, with the strongest quarterly revenue following in the second half of 2015. The company’s full-year 2015 revenues, comprised of systems, service, upgrades and disposables sales, are expected to be in the range of USD 40 million to USD 55 million. For the 2015 year, the company anticipates a higher gross profit margin of approximately 42% to 45%. The expected increase is a result of the company's multi-source sales strategy, growing services contribution that carry higher margins and completion of lower margin beta sites in prior years. The company forecasts capital expenditures in 2015 to be approximately USD 2.5 million.

IMRIS, Inc. to Report Q4, 2014 Results on Mar 04, 2015

IMRIS, Inc. announced that they will report Q4, 2014 results at 8:00 AM, Central Standard Time on Mar 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM:CN C$1.01 CAD +0.02

IM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $27.25 USD -0.03
Koninklijke Philips NV €26.45 EUR -0.405
Medtronic PLC $76.49 USD -0.53
Siemens AG €98.96 EUR -2.15
View Industry Companies

Industry Analysis


Industry Average

Valuation IM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMRIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at